MILAN, March 4, 2014 /PRNewswire/ --

BMG Pharma S.r.l. is pleased to announce that at the American Academy of Dermatology (AAD) in Denver, CO., BMG will offer to potential licensors two new products for specific dermatologic pathologies. As scar prevention and resolution gain increasing awareness in the marketplace, BMG is pleased to announce SCARTIVE® as the first product with the unique indications of pre-op scar prevention and post-op reduction of visible scars.

BMG has also developed a 3 part Aknekit™, which has been clinically proven to be non-inferior to traditional BPO, less irritating and it does not require  a warning against use in the sun.

A single blind clinical study over 5 years and on over 400 patients achieved statistical significance, showing that SCARTIVE® lipogel is effective for the prevention and reduction of scars.  SCARTIVE® gel was applied to the intended incision site three times a day for at least 15 days before scheduled surgery, and then  twice daily for at least 30 days post-surgery. The control group received topical petrolatum-based ointment.

A total of 96% of patients considered the results from SCARTIVE® lipogel  to be very good. No wound infection or development of keloids was noted in these patients. In the control group, 78% of patients considered the cosmetic results very good:   it was noted, that 13 (6.5%) patients developed keloids after 6 months and there were no cases of wound infection.

In the Aknekit™ multi-center clinical study, 102 patients were randomized between a benzoyl peroxide based product line and the new hydrogen peroxide based kit from BMG.

The results of the study show the products to be equally efficacious, safe and tolerable in the treatment of mild to moderate acne. The unique formulation of Aknekit™ from BMG provides the patient with the freedom to use the product when outdoors, without requiring a sunscreen label warning.  

BMG's CEO, Marco Mastrodonato comments: "We are seeking a strong partner and sales force to market SCARTIVE® and AKNEKIT™ in the US, with unique positioning for both products. These exciting new products bring a new level of safety and efficacy to patients suffering from these widely experienced conditions. Both products will be supported by scientific posters at the Academy.

About BMG Pharma S.r.l

BMG Pharma S.r.l. is a Specialty Pharmaceutical and Medical Device company leveraging its proprietary technology to develop products that address unmet needs of patients. The Company is currently focused on cancer supportive care, dermatology gynecology, ENT and oral health. BMG Pharma S.r.l. is dedicated to help patients, pharmacists and physicians by providing valuable and innovative products to the market.  

For press releases and other company information, visit: http://www.bmgpharma.com

USA Contact:
Mike Killeen
mike.killeen@bmgpharma.com 

Corporate:
Loredana Galli
loredana.galli@bmgpharma.com

+39(02)91321756

SOURCE BMG Pharma S.r.l.